Mes‐Acr + BF 4 − Catalyzed Visible‐Light Aerobic Synthesis of α ‐ketoamides From β ‐Keto Acids and Amines
ChemistrySelect · 2026-11 · 11 (41)
DOI: 10.1002/slct.74984 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemistrySelect, online erschienen am 28.10.2026. Verfasst von Ali Akbari und 1 weiteren Autor:innen. Die Arbeit nennt 50 Literaturangaben.
Abstract (Originalsprache)
A metal‐free and environmentally benign photocatalytic strategy has been developed for the construction of α‐ketoamides from readily accessible β ‐keto acids and amines under visible‐light irradiation. Using the organic photoredox catalyst Mes‐Acr + BF 4 − (9‐mesityl‐10‐methylacridinium tetrafluoroborate), this protocol eliminates the need for hazardous stoichiometric oxidants and iodine‐based reagents. The transformation proceeds through a photoinduced electron‐transfer pathway, generating radical intermediates that undergo oxygen‐dependent oxidation followed by amine incorporation and selective C–C bond cleavage. This cascade sequence furnishes a diverse range of α ‐ketoamide derivatives in moderate to good yields under mild, operationally simple, and scalable conditions. The method offers a sustainable and mechanistically well‐defined approach to valuable 1,2‐dicarbonyl scaffolds relevant to complex‐molecule synthesis and late‐stage functionalization.
Zitieren
APA
Akbari, A., & Raeisi‐garmeshk, Z. (2026). Mes‐Acr + BF 4 − Catalyzed Visible‐Light Aerobic Synthesis of α ‐ketoamides From β ‐Keto Acids and Amines. ChemistrySelect, 11(41). https://doi.org/10.1002/slct.74984
Vancouver
Akbari A, Raeisi‐garmeshk Z. Mes‐Acr + BF 4 − Catalyzed Visible‐Light Aerobic Synthesis of α ‐ketoamides From β ‐Keto Acids and Amines. ChemistrySelect. 2026;11(41). doi:10.1002/slct.74984
BibTeX
@article{Akbari2026,
author = {Akbari, Ali and Raeisi‐garmeshk, Zahra},
title = {Mes‐Acr + BF 4 − Catalyzed Visible‐Light Aerobic Synthesis of α ‐ketoamides From β ‐Keto Acids and Amines},
journal = {ChemistrySelect},
year = {2026},
volume = {11},
number = {41},
doi = {10.1002/slct.74984}
}
EUVIMED